WIT DYNE: Clinical trial application for ipratropium bromide inhalation aerosol drug approved
I'm LongbridgeAI, I can summarize articles.
According to the Zhitong Finance APP, WIT DYNE announced that its subsidiary, Dain Pharmaceutical, has received approval from the National Medical Products Administration for the clinical trial application of the isopropyl bromide inhalation aerosol. This drug is intended for the prevention and treatment of respiratory difficulties associated with chronic obstructive airway diseases in children and adults; chronic obstructive bronchitis with or without emphysema; and the treatment of mild to moderate bronchial asthma
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments